DNAJC21

Across TCGA pan-cancer cohorts, DNAJC21 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DNAJC21 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher DNAJC21 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated DNAJC21 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where DNAJC21 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.987	0.679	.001	23	view →
HNSC	DFS	Tertile	All	0.907	1.000	.008	21	view →
LUAD	OS	Tertile	III,IV	1.000	0.797	.022	4	view →
CCRCC	DFS	Median	All	0.575	0.861	.022	2	view →
GBM	OS	Tertile	All	0.743	0.877	.019	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DNAJC21–PDAC (OS)

Open the PDAC breakdown →